Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN versus OXYTOCIN 10 USP UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN versus OXYTOCIN 10 USP UNITS IN DEXTROSE 5.
OXYTOCIN vs OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxytocin is a nonapeptide hormone that binds to oxytocin receptors on the myometrium, stimulating G-protein coupled receptor activation and increasing intracellular calcium, leading to uterine smooth muscle contraction. It also acts on mammary gland myoepithelial cells to induce milk ejection.
Increases intracellular calcium in uterine myofibrils, stimulating contractions. Binds to oxytocin receptors in myometrium and mammary glands.
For induction/augmentation of labor: IV infusion, initial 0.5-2 mU/min, increase by 1-2 mU/min every 30-60 min until desired contraction pattern; max 20 mU/min. For postpartum hemorrhage: IV bolus 3 units (slow push) or IV infusion 10-40 units in 1000 mL crystalloid, rate adjusted to control bleeding; alternatively IM 10 units after delivery of placenta.
IV infusion: 0.5-2 mU/min, increased by 1-2 mU/min every 30-60 min until desired uterine activity, then reduce; max 20 mU/min.
None Documented
None Documented
Terminal elimination half-life: 1–6 minutes (intravenous); clinical context: rapid offset requires continuous infusion for sustained uterine contraction.
Terminal half-life: 1-6 minutes (IV); clinical effect ceases rapidly after infusion stops due to rapid clearance.
Renal: >99% as intact oxytocin and metabolites; biliary/fecal: negligible.
Renal: >99% as unchanged drug; <1% hepatic metabolism and biliary excretion.
Category C
Category C
Oxytocic
Oxytocic